Clinical trials: Tophaceous Gout
Gout, Gouty Arthritis
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase).
- Conditions
- Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic
- Trial name
- NCT07116746
- Testing
- AR882 75 mg, XOI Low Dose, XOI High Dose
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Arthrosi Therapeutics
Gout
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in patients with chronic gout, who cannot…
- Trial name
- NCT00111657
- Testing
- Pegloticase
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- John Sundy
Gout, Arthritis, Gouty
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.
- Conditions
- Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
- Trial name
- NCT05253833
- Testing
- AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet
- Where
- 12 sites in United States, New Zealand and 1 more
- Volunteers
- 42 people
- Sponsor
- Arthrosi Therapeutics
Recurrent or Tophaceous Gout
Evaluating the Effectiveness of a Chronic Disease Management Program for Gout
The aim of this study is to test the effectiveness of a pharmacist-staffed, protocol-based chronic disease management program compared to patients receiving usual care in achieving a target serum uric acid level in patients with…
- Trial name
- NCT01568879
- Testing
- Control, Gout Disease Management Program
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Kaiser Permanente
Tophaceous Gout
Evolution of Tophus and Erosions of Hands and Feet at DECT
The main objective is to evaluate the decrease in crystalline volume of the target tophus using Dual-Energy Computed Tomography (DECT), after 6 months +/- 1 month of urate-lowering therapy with target uricemia.
- Trial name
- TOPHERO-CT (NCT03965676)
- Testing
- Dual-Energy Computed Tomography examination
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
- Trial name
- NCT07089888
- Testing
- Allopurinol, Dotinurad
- Where
- 95 sites in United States
- Volunteers
- 250 people
- Sponsor
- Crystalys Therapeutics
Tophaceous Gout
Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase…
- Trial name
- NCT06186219
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, Los Angeles
Tophaceous Gout
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.
- Trial name
- CRYSTAL (NCT01510769)
- Testing
- Lesinurad, Febuxostat
- Where
- 124 sites in United States, Australia and 4 more
- Volunteers
- 330 people
- Sponsor
- Ardea Biosciences, Inc.